Identification of potential key genes that respond to capsaicin treatment in ER-positive breast cancer: An integrated analysis
Breast cancer remains a critical global public health challenge, characterized by increasing morbidity and mortality. In 2020, global data recorded 2,261,419 new cases and 684,996 deaths worldwide.
A significant portion of these cases, approximately 70% to 80%, are estrogen receptor-positive (ER-positive). While this subtype often has better survival outcomes, researchers continue to seek new therapeutic targets to improve patient prognosis.
The Role of Capsaicin in Cancer Research
Capsaicin, the active compound found in red peppers, is a phytochemical known for broad-spectrum anticancer activity. Previous studies have shown it can induce cell death and inhibit cell migration in breast cancer cells.
Despite these known effects, the exact molecular mechanisms capsaicin uses to fight ER-positive breast cancer have remained poorly understood. A recent integrated analysis has now identified specific genetic targets that respond to this compound.
Identifying SHMT2 and GARS as Key Targets
Using bioinformatic analysis and experimental validation, researchers identified two key genes: SHMT2 and GARS. Both genes were found to be overexpressed in breast cancer tissues compared to normal tissues.
The study demonstrated that capsaicin significantly reduces the expression of SHMT2 and GARS at both the mRNA and protein levels. This reduction occurred in a dose-dependent manner, effectively inhibiting the viability of ER-positive breast cancer cells.
Metabolic Reprogramming and Survival
SHMT2 is a key enzyme linking serine and glycine synthesis to one-carbon metabolism. High levels of SHMT2 are associated with poor overall survival and can promote tumor growth through specific signaling pathways.
Similarly, GARS is an indispensable enzyme for protein synthesis. The research indicates that high GARS expression may be linked to shorter relapse-free and distant metastasis-free survival for patients.
Impact on the Immune System
The study also explored how these genes affect the tumor microenvironment. High expression of SHMT2 and GARS appears to be associated with altered immune cell infiltration.
Specifically, high levels of these genes correlate with a decrease in antitumor cells, such as CD8+ T cells and activated NK cells. Conversely, they are linked to an increase in pro-tumor cells, including regulatory T cells and M2 macrophages.
Future Directions in Treatment
These findings generate new hypotheses regarding how capsaicin exerts its antitumor effects. Capsaicin modulates the immune system by downregulating SHMT2 and GARS.
A possible next step involves direct experimental validation, such as in vivo immune assays, to confirm these correlations. Future research may explore whether inactivating the STAT3 and Akt/mTOR pathways is the primary driver behind the downregulation of these genes.
Frequently Asked Questions
What are SHMT2 and GARS?
SHMT2 is an enzyme involved in serine/glycine synthesis and one-carbon metabolism, while GARS is an enzyme essential for protein synthesis in mammalian cells.
How does capsaicin affect these genes?
Capsaicin reduces the expression of SHMT2 and GARS at both the mRNA and protein levels, which in turn inhibits the viability of ER-positive breast cancer cells.
What is the link between these genes and the immune system?
High expression of SHMT2 and GARS is associated with lower infiltration of antitumor cells (like CD8+ T cells) and higher infiltration of pro-tumor cells (like regulatory T cells and M2 macrophages).
Do you believe natural phytochemicals will play a larger role in integrated cancer therapies in the future?